170 results
S-8
ENLV
Enlivex Therapeutics Ltd
4 Jun 21
Registration of securities for employees
4:16pm
the abovementioned foreseen events and amount or criteria;
reasonable litigation expenses, including reasonable attorneys’ fees, which were incurred … ;
expenses expended by the office holder with respect to an Administrative Procedure under the Securities Law, including reasonable litigation expenses
F-1/A
EX-3.2
ENLV
Enlivex Therapeutics Ltd
8 Jul 14
Registration statement (foreign) (amended)
12:00am
reasonable litigation expenses and attorney’s fees, expended by an Office Holder or which were imposed on an Office Holder by a court in proceedings filed … or a reasonable criterion under such circumstances as determined by the Board;
reasonable litigation expenses, including attorney’s fees, incurred by him
F-3
ENLV
Enlivex Therapeutics Ltd
28 Jun 19
Shelf registration (foreign)
9:48am
Forward-Looking Statements
This prospectus contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 … or an arbitrator’s decision approved by a court;
Reasonable litigation expenses, including attorney’s fees, incurred by the office holder in consequence
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
27 Mar 19
Securities Purchase Agreement
8:32am
as expenses, including reasonable litigation expenses and attorney’s fees, expended by an Office Holder or which were imposed on an Office Holder by a court … , and to a specific sum or a reasonable criterion under such circumstances as determined by the Board;
reasonable litigation expenses, including attorney’s fees
6-K
EX-99.1
nsyz8bfh rl97qqiuby0
25 Aug 20
Enlivex Announces Allowance of New U.S. Patent Covering Allocetra Immunotherapy
8:02am
6-K
EX-99.1
roa2q8vohj3gq 8o36tk
8 Mar 22
Enlivex Announces Issuance of Israeli Patent Covering Allocetra Derived from Pooled Donor Cells
8:03am
F-3
400l0rafl2dv wcj6
29 Apr 22
Shelf registration (foreign)
8:14am
6-K
EX-99.1
v8ppgfqtfr803k2ume
8 May 23
Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to
8:02am
6-K
EX-99.1
o5oi4lza
13 Apr 20
Enlivex Selected by the Israel Innovation Authority to Receive $1.5 Million Grant to Fund COVID-19 and Sepsis Clinical Trials
8:32am
6-K
EX-99.1
slg764x j5j
29 Aug 22
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells
8:01am
6-K
EX-99.1
65bixw
5 May 22
Enlivex Announces Issuance of Two U.S. Patents Covering Methods of Treating Sepsis with Allocetra
8:35am
6-K
EX-99.1
wr1y0sx39mbvcedx1i8
31 Jul 23
Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis
8:05am
6-K
op69l4i4158 mzt1
18 Sep 23
Report of Foreign Private Issuer
8:00am
6-K
EX-99.1
pp0636i
9 Oct 15
Appoints Former Aptalis and Novartis Executive, Theresa M. Stevens, as Chief Corporate Development Officer
12:00am
6-K
EX-99.1
6s4 sz0mp
6 Sep 22
Report of Foreign Private Issuer
8:06am
6-K
EX-99.1
61p8s59 3cdx
6 Mar 19
Bioblast Announces Effectiveness of Eight to One Reverse
6:15am
6-K
EX-99.1
mvo6dyyg2
31 May 23
Report of Foreign Private Issuer
8:09am
6-K
EX-99.1
4xsx6kq231k vnf35l
22 Sep 14
Bio Blast Pharma Announces Initiation of its Canadian OPMD Clinical Study Center at McGill University, Montreal
12:00am
6-K
EX-99.1
s3020hs
28 Nov 22
Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies
8:01am